Article Text

AB0606 Methotrexate does not seem to reactivate chronic viral C hepatitis: Preliminary data from a case-control study
  1. S. Slimani1,1,
  2. S. Bendekkiche2,
  3. A. Ladjouze-Rezig3
  1. 1Hadj Lakhdar University
  2. 2Medicine, EPH Barika, Batna
  3. 3Rheumatology, EHS Ben Aknoun, Algiers, Algeria


Background Chronic viral C hepatitis affects around 170 million people in the world. In some areas, prevalence is higher, it reaches 6% of the population of the urban district of Barika - Algeria. This constitutes a burden for the management of some affections, among them rheumatoid arthritis (RA) since some reports noted reactivation or worsening of viral C hepatitis under immunosuppressive therapies. Data concerning methotrexate in RA are scarce except few case reports, most of them were reassuring. We followed a cohort of patients presenting with RA associated with a Hepatitis C infection and treated with methotrexate (MTX), in order to detect any worsening or recurrence of their infection under methotrexate.

Methods Seven patients, all female, presenting with RA and chronic viral C hepatitis were enrolled in the study and followed up by a rheumatologist (SS) and a specialist in infectious diseases (SB). Mean age was 56.7 years and mean duration of RA 12 years. They all had an RA according to the 2010 ACR/EULAR criteria. They had a positive HCV test (Elisa confirmed by an ImmunoBlot). Methotrexate was given only when real-time PCR for HCV was negative, either initially or after a 48 week Interferon alpha + Ribavirine therapy. Moreover, patients with histological grading ≥ A2F2 were not included. A screening was established as follows: liver enzymes every 2 months, bilirubine and HCV PCR at 6 months from MTX initiation. A control group was created with 30 female RA patients, HCV-, matched for age and MTX doses. Liver enzymes levels were compared at M0 and M6 in HCV+ group and between HCV- and HCV+ groups by a Student T-test. Results were considered significant for p<0.05.

Results Are presented here the preliminary results. Mean follow-up duration under MTX was 7 months. Mean MTX dosage 14 mg/week. Six/seven patients achieved a EULAR response to MTX at M6, the mean reduction for DAS28 in the seven patients at M6 was significant (p=0.035). Liver enzymes levels were stable between M0 and M6 (p=0.845) and no patient had presented levels >1.5 upper normal limit during the screening period. PCR HCV remained negative at M6 for the 7 patients and bilirubine remained in normal ranges. Comparison in liver enzymes levels at M6 between PR HCV+ and PR HCV- groups did not find differences (p=0.693).

Conclusions In our series of 7 patients presenting with a non-active C hepatitis and treated with methotrexate, we have not observed any reactivation of HCV during a 7 months follow-up. Results are preliminary because more patients are being included and a longer follow-up period is expected. Our results are reassuring and suggest that RA patients having HCV+ and HCV PCR- tests could be treated with MTX, but a tight control for liver enzymes and regular HCV PCR screening should be performed.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.